Savant Capital LLC Grows Holdings in Sanofi (NASDAQ:SNY)

Savant Capital LLC raised its stake in shares of Sanofi (NASDAQ:SNY) by 24.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,361 shares of the company’s stock after buying an additional 1,264 shares during the quarter. Savant Capital LLC’s holdings in Sanofi were worth $307,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Abel Hall LLC raised its position in Sanofi by 1.8% in the 4th quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after purchasing an additional 194 shares in the last quarter. PDS Planning Inc raised its position in Sanofi by 3.1% in the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after purchasing an additional 200 shares in the last quarter. Eagle Ridge Investment Management raised its position in Sanofi by 3.8% in the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock valued at $321,000 after purchasing an additional 203 shares in the last quarter. Financial Advocates Investment Management raised its position in Sanofi by 3.4% in the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after purchasing an additional 206 shares in the last quarter. Finally, Angeles Investment Advisors LLC raised its position in Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after purchasing an additional 210 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Trading Up 0.9 %

Shares of SNY stock opened at $54.50 on Tuesday. The business’s 50 day moving average is $50.42 and its two-hundred day moving average is $52.47. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a market capitalization of $138.31 billion, a P/E ratio of 21.89, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 0.74 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. Equities analysts forecast that Sanofi will post 4.36 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on SNY shares. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Sanofi presently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.